Oncotarget

Research Papers:

EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy

Yun-Tian Li, Xiao-Jun Qian, Yan Yu, Zhen-Hua Li, Rui-Yan Wu, Jiao Ji, Lin Jiao, Xuan Li, Peng-Fei Kong, Wen-Dan Chen, Gong-Kan Feng, Rong Deng and Xiao-Feng Zhu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:17491-17500. https://doi.org/10.18632/oncotarget.3959

Metrics: PDF 1383 views  |   HTML 1531 views  |   ?  


Abstract

Yun-Tian Li1,*, Xiao-Jun Qian1,2,*, Yan Yu1,*, Zhen-Hua Li3, Rui-Yan Wu1, Jiao Ji1, Lin Jiao1, Xuan Li1, Peng-Fei Kong1, Wen-Dan Chen1, Gong-Kan Feng1, Rong Deng1 and Xiao-Feng Zhu1

1 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Cancer Center, Sun Yat-sen University, Guangzhou, China

2 Department of Oncology, Anhui Provincial Hospital, Affiliated to Anhui Medical University, Hefei, China

3 The School of Medicine, Jinan University, Guangzhou, China

* These authors have contributed equally to this work

Correspondence to:

Xiao-Feng Zhu, email:

Keywords: EGFR inhibitors, doxorubicin, breast cancer, caspase-8, sequential application

Received: February 11, 2015 Accepted: April 09, 2015 Published: April 29, 2015

Abstract

The combination of time and order-dependent chemotherapeutic strategies has demonstrated enhanced efficacy in killing cancer cells while minimizing adverse effects. However, the precise mechanism remains elusive. Our results showed that pre-treatment of MCF-7 and MDA-MB-468 cells with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib or lapatinib significantly enhanced the cytotoxic effects of DNA-damaging agents compared to coadministration of the EGFR inhibitor and DNA-damaging agent. Sequential application of erlotinib and doxorubicin increased activated caspase-8 by promoting pro-caspase-8 homodimerization and autocatalytical cleavage, whereas coadministration did not. We found that EGFR inhibitors promoted pro-caspase-8 homodimerization by inhibiting ERK pathway signaling, while doxorubicin promoted it. Our data highlight that ERK has the potential to inhibit the formation of pro-caspase-8 homodimers by phosphorylating pro-caspase-8 at S387. In conclusion, the pretreatment of EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging agents. Our findings provide rationale for novel strategies for the implementation of combined targeted and cytotoxic chemotherapy within a new framework of time and order-dependent therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3959